Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock
2023年8月2日 - 5:01AM
Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease
biopharmaceutical company developing novel therapeutics for the
treatment of pathologic mineralization and intimal proliferation,
today announced the closing of its underwritten public offering of
14,375,000 shares of its common stock at a price of $4.80 per
share. The shares of common stock issued and sold in the public
offering at the closing include 1,875,000 shares issued upon the
exercise in full by the underwriters of their option to purchase
additional shares at the public offering price, less the
underwriting discounts and commissions. All of the shares of common
stock in the public offering were sold by Inozyme.
Inozyme received net proceeds of approximately
$64.5 million from the offering, after deducting underwriting
discounts and commissions and estimated offering expenses.
Purchasers in the offering included a select
group of healthcare focused institutional investors, including new
and existing investors.
BofA Securities, TD Cowen and Piper Sandler
acted as joint book-running managers for the offering. Wedbush
PacGrow and Needham & Company acted as co-managers for the
offering.
A shelf registration statement on Form S-3 (File
No. 333-258702) relating to the shares of common stock offered in
the public offering was filed with the Securities and Exchange
Commission (the “SEC”) on August 11, 2021 and became effective on
August 23, 2021. The offering was made only by means of a
prospectus supplement and accompanying prospectus that form a part
of the registration statement. A final prospectus supplement
relating to the offering has been filed with the SEC and may be
obtained for free by visiting the SEC’s website at www.sec.gov.
Copies of the final prospectus supplement and the accompanying
prospectus relating to the offering may also be obtained by
contacting: BofA Securities, NC1-022-02-25, 201 North Tryon Street,
Charlotte, NC 28255-0001, Attn: Prospectus Department, or by email
at: dg.prospectus_requests@bofa.com; TD Cowen, 599 Lexington
Avenue, New York, NY 10022, or by email at Prospectus_ECM@cowen.com
or by telephone at (833) 297-2926; or Piper Sandler, Attention:
Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis,
Minnesota 55402, or by telephone at (800) 747-3924, or by email at
prospectus@psc.com.
This press release does not constitute an offer
to sell, or a solicitation of an offer to buy these securities, nor
shall there be any sale of, these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Inozyme Pharma, Inc.
Inozyme Pharma, Inc. is a clinical-stage rare
disease biopharmaceutical company developing novel therapeutics for
the treatment of diseases impacting the vasculature, soft tissue
and skeleton. Inozyme is developing INZ-701, an enzyme replacement
therapy, to address pathologic mineralization and intimal
proliferation which can drive morbidity and mortality in these
severe diseases. INZ-701 is currently in clinical trials for the
treatment of ENPP1 Deficiency and ABCC6 Deficiency.
Contacts
Investors:Inozyme PharmaStefan Riley, Director of IR and
Corporate Communications(857)
330-8871stefan.riley@inozyme.com
Media: SmithSolve Matt
Pera973-886-9150matt.pera@smithsolve.com
Inozyme Pharma (NASDAQ:INZY)
過去 株価チャート
から 4 2024 まで 5 2024
Inozyme Pharma (NASDAQ:INZY)
過去 株価チャート
から 5 2023 まで 5 2024